Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

PURPOSE: Statins have antilymphoma properties but have also been shown to inhibit the binding of rituximab to the CD20 antigen, resulting in reduced antitumor activity of rituximab in vitro. The clinical impact of statin use on the outcome of lymphoma patients treated with a rituximab-containing reg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nowakowski, Grzegorz S., Maurer, Matthew J., Habermann, Thomas M., Ansell, Stephen M., Macon, William R., Ristow, Kay M., Allmer, Cristine, Slager, Susan L., Witzig, Thomas E., Cerhan, James R.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2815703/
https://ncbi.nlm.nih.gov/pubmed/20008638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.4245
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars